BRPI1011046A2 - derivados de isoquinolin-1 (2h)-ona como inibidores de parp-i - Google Patents
derivados de isoquinolin-1 (2h)-ona como inibidores de parp-iInfo
- Publication number
- BRPI1011046A2 BRPI1011046A2 BRPI1011046A BRPI1011046A BRPI1011046A2 BR PI1011046 A2 BRPI1011046 A2 BR PI1011046A2 BR PI1011046 A BRPI1011046 A BR PI1011046A BR PI1011046 A BRPI1011046 A BR PI1011046A BR PI1011046 A2 BRPI1011046 A2 BR PI1011046A2
- Authority
- BR
- Brazil
- Prior art keywords
- parp
- isoquinolin
- inhibitors
- derivatives
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09160869 | 2009-05-21 | ||
| EP09160869.5 | 2009-05-21 | ||
| PCT/EP2010/056921 WO2010133647A1 (en) | 2009-05-21 | 2010-05-19 | Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1011046A2 true BRPI1011046A2 (pt) | 2016-03-15 |
| BRPI1011046B1 BRPI1011046B1 (pt) | 2020-02-27 |
Family
ID=42372343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011046-1A BRPI1011046B1 (pt) | 2009-05-21 | 2010-05-19 | Derivados de isoquinolin-1 (2h)-ona como inibidores de parp-i |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8592416B2 (pt) |
| EP (1) | EP2432765B1 (pt) |
| JP (1) | JP5731486B2 (pt) |
| CN (1) | CN102438986B (pt) |
| AR (1) | AR076688A1 (pt) |
| AU (1) | AU2010251112B2 (pt) |
| BR (1) | BRPI1011046B1 (pt) |
| CA (1) | CA2762226C (pt) |
| CL (1) | CL2011002925A1 (pt) |
| DK (1) | DK2432765T3 (pt) |
| EA (1) | EA023112B1 (pt) |
| ES (1) | ES2568936T3 (pt) |
| MX (1) | MX2011012187A (pt) |
| TW (1) | TWI499418B (pt) |
| WO (1) | WO2010133647A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| FR2956816B1 (fr) * | 2010-03-01 | 2012-05-18 | Univ Joseph Fourier | Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese |
| WO2013014038A1 (en) | 2011-07-26 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors |
| CA2856759A1 (en) * | 2011-11-25 | 2013-05-30 | Nerviano Medical Sciences S.R.L. | 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
| EP2822656B1 (en) | 2012-03-07 | 2016-10-19 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| LT2882714T (lt) | 2012-08-08 | 2020-03-10 | Merck Patent Gmbh | (azo-)izochinolinono dariniai |
| SG11201502120XA (en) | 2012-09-26 | 2015-04-29 | Merck Patent Gmbh | Quinazolinone derivatives as parp inhibitors |
| US9290454B2 (en) | 2012-10-01 | 2016-03-22 | Merck Sharp & Dohme Corp. | Substituted isoquinolines as CRTH2 receptor modulators |
| US10385018B2 (en) | 2012-10-26 | 2019-08-20 | Nerviano Medical Sciences S.R.L. | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors |
| AU2014320149A1 (en) | 2013-09-11 | 2016-04-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| EP3265560B1 (en) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologous recombination factors |
| US11096909B2 (en) | 2016-04-06 | 2021-08-24 | University Of Oulu | Compounds for use in the treatment of cancer |
| CN106083716B (zh) * | 2016-06-07 | 2018-10-30 | 温州医科大学仁济学院 | 一种3-芳基异喹啉化合物的制备方法 |
| US9891509B2 (en) | 2016-06-17 | 2018-02-13 | Mimono LLC | Projector holder |
| US10899733B2 (en) | 2017-08-23 | 2021-01-26 | Oregon Health & Science University | Inhibitors of PARPs that catalyze mono-ADP-ribosylation |
| WO2019232223A1 (en) | 2018-05-30 | 2019-12-05 | University Of Notre Dame Du Lac | Hsp90 beta selective inhibitors |
| CN113549044B (zh) * | 2021-07-23 | 2024-01-23 | 中国药科大学 | 8-氮杂环取代色酮类衍生物及其制备方法与制药用途 |
| WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
| CN121079090A (zh) | 2023-05-11 | 2025-12-05 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的parp1抑制剂和选择性雌激素降解剂的组合 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59116269A (ja) * | 1982-12-24 | 1984-07-05 | Nisshin Flour Milling Co Ltd | イソカルボスチリル誘導体 |
| JPS60237070A (ja) * | 1984-05-08 | 1985-11-25 | Nisshin Flour Milling Co Ltd | 光学活性イソカルボスチリル誘導体の製法 |
| DK0389995T3 (da) | 1989-03-28 | 1995-07-03 | Nisshin Flour Milling Co | Isoquinolinderivater til behandling af glaukom eller okular hypertension |
| JP3141051B2 (ja) | 1992-10-09 | 2001-03-05 | 日清製粉株式会社 | 抗動脈硬化剤 |
| SE9902268D0 (sv) * | 1999-06-16 | 1999-06-16 | Astra Ab | Pharmaceutically active compounds |
| EP1397350B1 (en) * | 2001-05-08 | 2007-02-28 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| WO2004031171A1 (ja) * | 2002-10-01 | 2004-04-15 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| CA2507027C (en) * | 2002-11-22 | 2012-05-08 | Mitsubishi Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
| DE102004028973A1 (de) * | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| CN101583601B (zh) | 2007-01-17 | 2013-06-05 | 香港科技大学 | 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物 |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
-
2010
- 2010-05-17 TW TW099115650A patent/TWI499418B/zh active
- 2010-05-18 AR ARP100101720A patent/AR076688A1/es active IP Right Grant
- 2010-05-19 EP EP10723046.8A patent/EP2432765B1/en active Active
- 2010-05-19 ES ES10723046.8T patent/ES2568936T3/es active Active
- 2010-05-19 AU AU2010251112A patent/AU2010251112B2/en active Active
- 2010-05-19 MX MX2011012187A patent/MX2011012187A/es active IP Right Grant
- 2010-05-19 BR BRPI1011046-1A patent/BRPI1011046B1/pt active IP Right Grant
- 2010-05-19 US US13/320,969 patent/US8592416B2/en active Active
- 2010-05-19 DK DK10723046.8T patent/DK2432765T3/en active
- 2010-05-19 CA CA2762226A patent/CA2762226C/en active Active
- 2010-05-19 JP JP2012511282A patent/JP5731486B2/ja active Active
- 2010-05-19 CN CN201080021942.8A patent/CN102438986B/zh active Active
- 2010-05-19 WO PCT/EP2010/056921 patent/WO2010133647A1/en not_active Ceased
- 2010-05-19 EA EA201171448A patent/EA023112B1/ru not_active IP Right Cessation
-
2011
- 2011-11-18 CL CL2011002925A patent/CL2011002925A1/es unknown
-
2013
- 2013-10-23 US US14/061,100 patent/US8993594B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2432765B1 (en) | 2016-03-02 |
| CN102438986A (zh) | 2012-05-02 |
| CA2762226C (en) | 2017-12-05 |
| EP2432765A1 (en) | 2012-03-28 |
| HK1166076A1 (en) | 2012-10-19 |
| CL2011002925A1 (es) | 2012-04-13 |
| EA201171448A1 (ru) | 2012-06-29 |
| WO2010133647A1 (en) | 2010-11-25 |
| US20120157454A1 (en) | 2012-06-21 |
| US20140045846A1 (en) | 2014-02-13 |
| TWI499418B (zh) | 2015-09-11 |
| CA2762226A1 (en) | 2010-11-25 |
| TW201043232A (en) | 2010-12-16 |
| AR076688A1 (es) | 2011-06-29 |
| US8993594B2 (en) | 2015-03-31 |
| CN102438986B (zh) | 2015-07-01 |
| AU2010251112A1 (en) | 2012-01-19 |
| US8592416B2 (en) | 2013-11-26 |
| DK2432765T3 (en) | 2016-04-25 |
| ES2568936T3 (es) | 2016-05-05 |
| MX2011012187A (es) | 2012-01-27 |
| EA023112B1 (ru) | 2016-04-29 |
| AU2010251112A2 (en) | 2012-02-02 |
| BRPI1011046B1 (pt) | 2020-02-27 |
| JP5731486B2 (ja) | 2015-06-10 |
| AU2010251112B2 (en) | 2015-11-12 |
| JP2012527428A (ja) | 2012-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011046A2 (pt) | derivados de isoquinolin-1 (2h)-ona como inibidores de parp-i | |
| ES2598358T8 (es) | Derivados de quinolina como inhibidores de PI3K quinasa | |
| BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
| BR112012002662A2 (pt) | derivados de bis-benzimidazol | |
| BR112012004969A2 (pt) | derivados de bis-benzimidazol | |
| BRPI1013246A2 (pt) | derivados de benzofuralina | |
| BR112012002828A2 (pt) | derivados de 5-fluorpirimidinona | |
| EP2480576A4 (en) | PCSK9 ANTAGONISTS | |
| BRPI1008749A2 (pt) | Derivados de benzodiazepina | |
| BRPI0811065A2 (pt) | Indazóis 5-heteroaril substituídos como inibidores de quinase | |
| BRPI0812825A2 (pt) | Derivados ftalazinona como inibidores de parp-1 | |
| EP2498607A4 (en) | Kinase Inhibitors | |
| EP2493313A4 (en) | Kinase Inhibitors | |
| BR112012000525A2 (pt) | inibidores da bace | |
| BRPI0913580A2 (pt) | pirrolopiridinas como inibidores de quinase | |
| BR112012015868A2 (pt) | derivados de imidazolidinadiona | |
| BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
| ECSP12011999A (es) | Derivados benzamida sustituidos | |
| BRPI1016189A2 (pt) | compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2 | |
| EP2558099A4 (en) | Kinase inhibitors | |
| BR112012008108A2 (pt) | derivados de xantina substituídos | |
| BRPI1013844A2 (pt) | derivados de piridina-isoxazol | |
| DK2397480T3 (da) | Diazepindionderivat | |
| UY33155A (es) | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa | |
| DOP2011000397A (es) | Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination | ||
| B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law | ||
| B09A | Decision: intention to grant | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2010, OBSERVADAS AS CONDICOES LEGAIS. |